KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, Mark van Duin, Evangelos Terpos, Mattia D'Agostino, Vincent H J van der Velden, Niels W C J van de Donk, Michel Delforge, Christoph Driessen, Roman Hajek, Hermann Einsele, Annette Vangsted, Diego Vieyra, Ricardo Attar, Anna Sitthi-Amorn, Robin Carson, Fredrik Schjesvold, Pawel Robak, Meral Beksac, Andrew Spencer, Annemiek Broijl, Tom Cupedo, Philippe Moreau, Mario Boccadoro, Pieter Sonneveld

Blood 147(4) 431-442

PMID41060326
PMCIDPMC12883856
DOI10.1182/blood.2025030113
发表日期2025-10-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving daratumumab/bortezomib/lenalidomide/dexamethasone (D-VRd) remains unknown. In this study, we analyzed CTC in the phase 3 PERSEUS/EMN017 trial. TE-NDMM patients were randomized (1:1) to D-VRd with daratumumab/lenalidomide maintenance (D-VRd group) or bortezomib/lenalidomide/dexamethasone (VRd) with lenalidomide maintenance (VRd group), both with transplant. A subset of 451 of 709 patients from PERSEUS (D-VRd, 231/355; VRd, 220/354) had screening blood samples collected for CTC analysis by flow cytometry. CTC were detected in 370 patients (82%; median limit of detection, 0.0004%). CTC were prognostic of progression-free survival (PFS), independent of other factors, as a continuous (hazard ratio [HR], 1.36 [95% confidence interval (CI), 1.15-1.60]; P< .001) and categorical variable (≥0.175% CTC-high, optimal threshold). D-VRd improved PFS vs VRd in CTC-low patients (4-year rates: 88% vs 74%; HR, 0.42 [95% CI, 0.25-0.70]; P = .0013). Regardless of study treatment, minimal residual disease (MRD)-negativity rates were lower in CTC-high vs CTC-low patients (10-5: 52.2% vs 66.2%; 10-6: 34.8% vs 52.4%). D-VRd significantly increased MRD-negativity rates vs VRd among CTC-high (10-5: 69.4% vs 33.3%; 10-6: 47.2% vs 21.2%; both P< .05) and CTC-low patients (10-5: 74.4% vs 57.8%; 10-6: 65.6% vs 38.5%; both P< .001), with similar observations for sustained MRD-negativity. CTC levels are an independent prognostic factor in TE-NDMM treated with standard-of-care frontline quadruplet. D-VRd improved and sustained MRD-negativity rates in CTC-high and CTC-low, and improved PFS for CTC-low with a positive trend in CTC-high patients. This trial was registered at www.clinicaltrials.gov as #NCT03710603.

KM 提取结果

3 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2. Prognostic impact of varying CTC levels and its independence of other risk factors. (A) Estimated PFS is progressively inferior in patients with increasing (log 10 ) levels of CTC. (B) Cox regression model including other well established risk factors (ISS, cytogenetics, and LDH) and treatment shows independent prognostic impact of increasing CTC levels (continuous variable). a Comparison with standard-risk. High-risk cytogenetics is defined by the presence of del(17p), t(4;14), and/or t(14;16) by fluorescence in situ hybridization. Absence of those is considered standard-risk.

A

progression-free survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Figure 3

Figure 3. Prognostic impact of CTC levels (high vs low) with optimal threshold and treatment. (A) Elevated CTC (CTC-high) with an optimal threshold (0.175%) show impact on PFS in the study population (n = 451). (B) Impact of CTC levels and treatment in PERSEUS study, where treatment with D-VRd improved outcomes in CTC-low patients but did not fully overcome the high risk portended by CTC-high. CTC-high is defined by CTC ≥0.175%; CTC-low is defined by CTC <0.175%.

A

Progression-free survival

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival

Figure 3 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Figure 5

Figure 5. MRD modulates the impact of CTC levels at diagnosis. (A) Landmark analysis (12 months from start of therapy) of PFS outcomes shows how achievement of MRD negativity (10 –6 threshold) modulates outcome of patients stratified by CTC levels at diagnosis. (B) Landmark analysis (24 months from start of therapy) shows similar PFS outcomes in patients with sustained (≥12 months) MRD negativity (10 –6 threshold) regardless of their CTC levels. CTC-high is defined by CTC ≥0.175%; CTC-low is defined by CTC <0.175%.

A

Progression-free survival

Figure 5 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival

Figure 5 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. CTC testing in the PERSEUS trial. Consort diagram reporting screened NDMM in the PERSEUS trial, and those with available samples at diagnosis that were analyzed by flow cytometry to detect and count CTC.
非 KM Figure
Figure 4Figure 4. MRD by next-generation sequencing and CTC levels at diagnosis. Rates of overall MRD negativity (A) and sustained (≥12 months) MRD negativity (B) are higher in CTC-low patients compared to CTC-high patients (10 –5 and 10 –6 threshold). Rates of overall MRD negativity (C) and sustained (≥12 months) MRD negativity (D) are higher with D-VRd compared to VRd in both CTC-low and CTC-high patients (10 –5 and 10 –6 threshold). CTC-high is defined by CTC ≥0.175%; CTC-low is defined by CTC <0.175%. Proportion of randomized patients who achieved both MRD negativity and ≥CR are included in the intention-to-treat population. Sustained MRD is defined as 2 consecutive MRD-negative results ≥12 months apart with no MRD-positive results in between. Bars over bar plots represent results of statistical test of 10 –5 threshold comparison (adjusted P values: ∗∗∗∗ P < .0001; ∗∗∗ P < .001; ∗∗ P < .01; ∗ P < .05; P values >.05 are not shown; based on χ 2 test). neg, negative.
非 KM Figure